Clinical Trial

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2027-06 2026-06-17
minor Completion pushed: 2026-06 -> 2027-06 2026-06-17
Trial Details
NCT Number NCT03096418
Lead Sponsor University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)
Conditions Breast Neoplasm Female
Enrollment 50 participants
Start Date 2017-03-13
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-16